Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, posted on X by Rafael Fonseca, Hematologist at Mayo Clinic, adding:
“One of the most eloquent arguments about 2nd-line CAR-T in multiple myeloma I’ve ever seen – thanks for sharing your wisdom on this, Rafael!
In a different universe where CAR-T had come first, we would be reserving 2L D-Pd, Isa-Kd etc only for older frailer patients – wouldn’t even be debated.”
Quoting Rafael Fonseca‘s post:
“Using CARTs for first relapse in myeloma.”
More posts featuring Rahul Banerjee and Rafael Fonseca on OncoDaily.